Frazier Life Sciences

Frazier Life Sciences is a biotech investment firm that manages over $6.9 billion in assets across venture and public strategies, investing in companies developing novel therapeutic drugs. Since 2015, the firm has created 25 companies, participated in over 50 IPOs and M&As worth more than $75 billion, and backed portfolio companies that have brought 75+ FDA-approved drugs to market across oncology, orphan diseases, and other therapeutic areas.